跳至主要内容
临床试验/JPRN-UMIN000038892
JPRN-UMIN000038892已完成未知

Cost-effectiveness analysis of EGFR T790M mutant testing after acquired resistance to 1st/2nd generation EGFR-TKI in unresectable/recurrent non-small cell lung cancer - Cost-effectiveness analysis of EGFR T790M mutant testing after acquired resistance to 1st/2nd generation EGFR-TKI in unresectable/recurrent non-small cell lung cancer

The University of Tokyo, Faculty of Medicine0 个研究点目标入组 0 人开始时间: 2019年12月15日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) patients treated with immunocheckpoint inhibitors after acquired resistance 1st/2nd generation EGFR-TKI 2) patients received at least 1 regimen of anti tumor therapy within 3 months prior to initiation of 1st/2nd generation EGFR-TKI treatment 3) complicated by haemophilia 4) complicated by leukaemia 5) complicated by severe heart failure

研究者

发起方
The University of Tokyo, Faculty of Medicine

相似试验